The Patent Finder

Nanirx, Inc.

Also on record
Records under this name other than patents Nanirx, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 5 of 5 · Back to Nanirx, Inc.

PatentTitleStatus Expires Confidence
US 7,927,580Tat-based immunomodulatory compositions and methods of their discovery and use
Formerly held
Term ended
Term ended Jul 7, 2026 · From the USPTO record
Term endedTerm ended Jul 7, 2026From the USPTO record
US 9,206,239Treatment of cancers with immunostimulatory HIV Tat derivative polypeptides
Formerly held
Lapsed on the fee record
Ended Dec 8, 2023 · From the USPTO record
Lapsed on the fee recordEnded Dec 8, 2023From the USPTO record
US 8,530,431Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
Formerly held
Lapsed on the fee record
Ended Sep 10, 2021 · From the USPTO record
Lapsed on the fee recordEnded Sep 10, 2021From the USPTO record
US 6,667,151Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) trans-activator of transcription protein for the treatment and prevention of HIV disease
Formerly held
Term ended
Term ended Aug 10, 2020 · From the USPTO record
Term endedTerm ended Aug 10, 2020From the USPTO record
US 8,323,928Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease
Formerly held
Term ended
Term ended Aug 10, 2020 · From the USPTO record
Term endedTerm ended Aug 10, 2020From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited